Posted by SLS on January 5, 2023, at 12:03:10
In reply to Re: Bipolar and constipation p.s. » SLS, posted by undopaminergic on January 4, 2023, at 4:22:28
Sorry, UD.
> > Abilify, like other D2 antagonists, increases That might add an increase in dopamine release, but mostly at low dosages.
My proofreading really sucks. Here is a better portrayal:
Abilify, like other antpsychotics, is a full antagonist at presynaptic D2 autoreceptors. This increases the manufacture and release of dopamine. However, unlike most other antipsychotics, Abilify is a partial agonist at the postsynaptic D2 receptor rather than being a full antagonist there. This supposedly renders Abilify as being a dopamine system stabilizer (DSS). As such, the postsynaptic action of Abilify depends on the intrasynaptic concentration of dopamine. At high dopamine concentrations, Abilify acts as a full antagonist at postsynaptic D2 receptors, thus reducing dopamine activity. However, when the intrasynaptic dopamine concentrations are low, Abilify acts more like an agonist than an antagonist of postsynaptic D2 receptors. Dopamine activity is increased.This most probably explains the following clinical guideline:
2-5 mg/day = treats depression - presynaptic D2 receptor antagonist + postsynaptic receptor agonist.
10-20 mg/day = treats bipolar mania - presynaptic D2 receptor antagonist + postsynaptic receptor antagonist.
20-30 mg/day = treats schizophrenia, schizoaffective disorder, and idiopathic psychosis - presynaptic D2 receptor antagonist + postsynaptic D2 receptor antagonist.
- ScottSome see things as they are and ask why.
I dream of things that never were and ask why not.The only thing necessary for the triumph of evil is that good men do nothing.
poster:SLS
thread:1121386
URL: http://www.dr-bob.org/babble/20220917/msgs/1121491.html